News

Tirzepatide Cut Adolescent BMI 18.5% in 72 Weeks, With GI Side Effects in Four of Five

Topics: tirzepatide adolescents, SURMOUNT-ADOLESCENTS, pediatric obesity, GLP-1 teenagers, JAMA tirzepatide trial, adolescent BMI reduction, GLP-1 side effects

What Happened

A phase 3 randomized trial of tirzepatide in teenagers is now in print. SURMOUNT-ADOLESCENTS published November 16 in JAMA and enrolled 160 adolescents aged 12 to just under 18 at 31 sites in six countries.

Participants had obesity (BMI at or above the 95th percentile) or overweight with at least one weight-related complication. After a 12-week lifestyle lead-in they were randomized two to one to weekly tirzepatide, escalated to a maximum tolerated dose, or placebo, and followed for 72 weeks. Mean BMI was 38.6 at a mean body weight of 109.7 kg — severe, not borderline, obesity.

At week 72, BMI fell 18.5 percent on tirzepatide and rose 0.5 percent on placebo, a treatment difference of 19.0 percentage points (95% CI, -23.9 to -14.1; P < .001). 79.6 percent of treated adolescents cut BMI by at least 5 percent against 28.5 percent on placebo; 48.1 percent cut at least 20 percent against 7.9 percent. 53.5 percent fell below the 95th-percentile obesity threshold versus 7.1 percent on placebo, and body weight dropped 16.9 percent against a 2.2 percent gain.

Tolerability was the price of entry. Adverse events occurred in 95.4 percent of treated participants and 82.4 percent of the placebo arm, with gastrointestinal effects in 81.5 percent versus 54.9 percent. 9.3 percent of the tirzepatide group stopped for side effects versus none on placebo; serious events occurred in 7.4 percent versus 3.9 percent. Depression or suicidal ideation was recorded in five treated adolescents (4.6 percent) and one on placebo (2.0 percent); none were serious and all who reported ideation had a documented psychiatric history. Height and pubertal progression tracked placebo — the trial's answer to the growth question hanging over pediatric incretin data.

Who Is Affected

  • Families of teenagers with severe obesity, who now have a 72-week randomized result to weigh against side effects in four of five patients
  • Pediatric endocrinologists, fielding requests for a drug with no approved adolescent indication in the United States
  • Payers, facing a chronic weekly injectable in the fastest-growing drug category

Timeline

  • October 2023 — Enrollment opens at 31 sites in six countries
  • June 2026 — Enrollment closes
  • November 16, 2026 — Primary results published in JAMA
  • 72 weeks — Primary endpoint; no data beyond it, and none after stopping treatment

What This Means for Researchers

Three details matter more than the headline number. Discontinuation ran higher on placebo (31.4 percent) than on tirzepatide (21.1 percent), mostly for lack of efficacy — differential dropout that complicates any per-protocol reading of effect size. The cohort was 83 percent White, with one participant in the overweight band and one case of type 2 diabetes, so the trial answers a narrow question: what happens in adolescents who already have severe obesity. And most participants had reached Tanner stage 5, which limits what the growth data can say about earlier puberty. Whether the effect survives withdrawal is unmeasured, and the sponsor funded the work.

How to Verify Your Peptides

For laboratory use, every vial should carry a batch-specific certificate of analysis, identity confirmed by mass spectrometry and purity by HPLC. Our guides on how testing works, HPLC versus LC-MS and identity, purity and fill weight explain what a report must show.

Safe Alternatives

Treatment for an adolescent with obesity belongs with a pediatric weight-management program and a physician, not a research supplier. Our compound pages document trial data and regulatory status for tirzepatide and semaglutide, and the vendor directory lists suppliers that publish third-party testing.

Sources

  • JAMA, SURMOUNT-ADOLESCENTS trial report (doi:10.1001/jama.2026.23420)
  • ClinicalTrials.gov record NCT06075667

Related Peptides & Topics

tirzepatide adolescents SURMOUNT-ADOLESCENTS pediatric obesity GLP-1 teenagers JAMA tirzepatide trial adolescent BMI reduction GLP-1 side effects